Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men

Source: https://dailynews.ascopubs.org/do/10.1200/ADN.22.200920/full/
Original Article
Professional photo of Lucio Gordan, MD
MACE risk following ADT initiation was higher for older patients compared with younger patients. All comparisons were significant with a P value of < 0.05.
FCS medical oncologist Dr. Lucio Gordan is the lead investigator of this study utilizing data from more than 44,000 patients which demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).

KEY POINTS

  • Electronic medical records from more than 44,000 patients demonstrate that the overall risk of major adverse cardiovascular events (MACE) is low in men with prostate cancer treated with androgen deprivation therapy (ADT).
  • The risk of MACE is higher in older men with prostate cancer treated with ADT compared with younger men.
  • The overall MACE risk was similar at both 1 and 7 years after ADT initiation.
The risk of major adverse cardiovascular events (MACE) following the initiation of androgen deprivation therapy (ADT) in men with prostate cancer is higher for older men compared with their younger counterparts. However, the overall MACE risk at 1 year in all age groups starting ADT is 1% or less, which is much lower than previously published reports. The findings, gleaned from analyses of U.S. electronic medical records, were presented during the virtual National Comprehensive Cancer Network 2022 Annual Meeting.

1 thought on “Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men”

  1. K.S.Kumar

    A large retrospective VA study presented at ASCO 2020 reported increased MACE and more so with Agonists than antagonists. So I am skeptical about this EMR review data and it dose not differentiate Agonist vs antagonist; For patients with pre-existing or high risk I choose direct antagonists than agonists. Also to be noted there are increasing data that Abiratarone is associated with increase cardiovascular events.

    Reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.

Read More »

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Pasritamig was administered to patients who had received a median of four prior lines of systemic therapy. It was well tolerated, with manageable adverse events, making it suitable for outpatient administration. The treatment showed a median radiographic progression-free survival of 7.85 months, and 14 out of 33 participants achieved a ≥50% reduction in baseline PSA levels. So, stay tuned.

Read More »
Load More